Francesca Micoli, PhD GSK Vaccines

Francesca has a PhD in industrial organic chemistry awarded at the University of Florence, Italy, in 2006. From 2007 working in GSK Vaccines Institute for Global Health (Siena, Italy), focusing her research on the development of effective and affordable vaccines for neglected diseases in impoverished communities. Involved in the development of vaccines against Salmonella Typhi, Salmonella Paratyphi A, non-typhoidal Salmonella, Shigella, Group A Streptococcus and Neisseria meningitidis. She has been Technology Platform Head at GVGH, working on two main technology platforms, glycoconjugation and Generalised Modules for Membrane Antigens (GMMA). From April 2020, Senior Project Leader of the Shigella project and more recently also Director of the Innovation Academy, focused on innovative technologies for vaccine development. Author of more than 80 scientific publications and several patent applications, with many collaborations in place with academic and industrial partners. Board member of the MRC-funded BactiVac, the first bacterial vaccine network, with a LMIC-centric focus.